Episode Details

China just approved a local drugmaker’s weight-loss medicine, effectively ending Novo Nordisk and Eli Lilly’s two-horse race, while US utility firms are set to make record infrastructure investments – but Big Tech may still go entirely off-grid.

Today’s stories:

• Novo Nordisk And Eli Lilly Have A Rival In The Weight-Loss Drug Fight
• America’s Utility Firms Are Powering Up Their Infrastructure Spending

Try Finimize Pro